恩替卡韦预防乙型肝炎病毒相关肝硬化的基因型依赖于恩替

StephenW

Effectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis
Kazuo Tarao  1 , Akito Nozaki  2 , Makoto Chuma  2 , Masataka Taguri  3 , Shin Maeda  4
Affiliations
Affiliations

    1
    Department of Gastroenterology, Tarao's Gastroenterological Clinic, Yokohama City 241-0821, Japan. [email protected].
    2
    Gastroenterological Center, Yokohama City University Medical Center, Yokohama 232-0024, Japan.
    3
    Department of Data Science, Yokohama City University School of Data Science, Yokohama 236-0004, Japan.
    4
    Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.

    PMID: 33584993 PMCID: PMC7856867 DOI: 10.4254/wjh.v13.i1.144

Free PMC article
Abstract

Background: The oral nucleos(t)ide analogue, entecavir (ETV) was demonstrated to reduce the rate of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV)-associated liver cirrhosis. However, the reduction of HCC differs in various regions of the world.

Aim: To investigate the reduction of HCC development due to ETV therapy by meta-analysis.

Methods: We surveyed the differences in HCC development following ETV treatment based on published articles using PubMed (2004-2019).

Results: The regions with the most marked reduction in HCC development due to ETV therapy were Spain (1.0%/year) and Canada (Southern part, 1.3%/year), and the most ineffective areas were South Korea (3.6%-3.8%/year), China (3.3%/year), Taiwan (2.4%-3.1%/year), and Hong Kong (2.8%/year). Following ETV administration, the incidence of HCC in genotype D regions (1.89% ± 0.28%/year, mean ± SE) was significantly lower than that in genotype C regions (2.91% ± 0.24%/year, P < 0.01). With regard to the initial HBV-DNA level, in genotype C patients (average: 5.61 Log10IU/mL) this was almost the same as that in genotype D patients (average: 5.46 Log10IU/mL). Moreover, there was no association between the prevalence ratio of HBV and the incidence of HCC on ETV treatment.

Conclusion: The effectiveness of ETV in preventing HCC development in HBV-associated liver cirrhosis is genotype-dependent.

Keywords: Entecavir; Genotype of hepatitis B virus; Hepatocellular carcinoma; Oral nucleos(t)ide analogue.

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

StephenW

恩替卡韦预防乙型肝炎病毒相关肝硬化的基因型依赖于恩替卡韦的有效性
垂尾和一1，野崎昭2，中川诚2，田孝正3，前田新4
隶属关系
隶属关系

    1个
    日本横滨市太郎市胃肠病医院消化内科241-0821，日本。 [email protected]。
    2
    横滨市立大学医学中心胃肠病学中心，日本横滨232-0024。
    3
    横滨市立大学数据科学学院数据科学系，日本横滨236-0004。
    4
    横滨市立大学医学研究科胃肠病科，日本横滨236-0004。

    PMID：33584993 PMCID：PMC7856867 DOI：10.4254 / wjh.v13.i1.144

免费PMC文章
抽象的

背景：口服核苷类似物恩替卡韦（ETV）被证明可以降低乙型肝炎病毒（HBV）相关性肝硬化患者的肝细胞癌（HCC）发生率。但是，HCC的减少在世界各地有所不同。

目的：通过荟萃分析研究因ETV疗法而导致的肝癌发展的减少。

方法：我们根据发表在PubMed（2004-2019）上的文章，调查了ETV治疗后HCC发育的差异。

结果：ETV治疗使HCC发生减少最明显的地区是西班牙（1.0％/年）和加拿大（南部，1.3％/年），最无效的地区是韩国（3.6％-3.8％） /年），中国（3.3％/年），台湾（2.4％-3.1％/年）和香港（2.8％/年）。 ETV给药后，D基因型区域的HCC发生率（1.89％±0.28％/年，平均值±SE）显着低于C基因型区域的HCC发生率（2.91％±0.24％/年，P <0.01）。关于初始HBV-DNA水平，在基因型C患者中（平均：5.61 Log10IU / mL），这几乎与基因型D患者中的（平均：5.46 Log10IU / mL）相同。此外，在ETV治疗中，HBV的患病率与HCC的发生率之间没有关联。

结论：ETV预防HBV相关肝硬化的肝癌发展的有效性与基因型有关。

关键字：恩替卡韦；乙型肝炎病毒的基因型；肝细胞癌；口服核苷类似物。

StephenW

https://www.wjgnet.com/1948-5182/full/v13/i1/144.htm

miao64

我就是C型，吃了十多年的ETV都已经抗原转阴、结果还是发生了HCC！